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OBJECTIVES We tested the hypothesis that intramyocardial injection of autologous bone marrow (ABM)
promotes collateral development in ischemic porcine myocardium. We also defined, in vitro,
whether bone marrow (BM) cells secrete vascular endothelial growth factor (VEGF) and
macrophage chemoattractant protein-1 (MCP-1).
BACKGROUND The natural processes leading to collateral development are extremely complex, requiring multiple
growth factors interacting in concert and in sequence. Because optimal angiogenesis may,
therefore, require multiple angiogenic factors, we thought that injection of BM, which contains
cells that secrete numerous angiogenic factors, might provide optimal therapeutic angiogenesis.
METHODS Bone marrow was cultured four weeks in vitro. Conditioned medium was assayed for VEGF
and MCP-1 and was added to cultured pig aortic endothelial cells (PAEC) to assess
proliferation. Four weeks after left circumflex ameroid implantation, freshly aspirated ABM
(n 5 7) or heparinized saline (n 5 7) was injected transendocardially into the ischemic zone
(0.2 ml/injection at 12 sites). Echocardiography to assess myocardial thickening and
microspheres to assess perfusion were performed at rest and during stress.
RESULTS Vascular endothelial growth factor and MCP-1 concentrations increased in a time-related
manner. The conditioned medium enhanced, in a dose-related manner, PAEC proliferation.
Collateral flow (ischemic/normal zone 3 100) improved in ABM-treated pigs (ABM: 98 6
14 vs. 83 6 12 at rest, p 5 0.001; 89 6 18 vs. 78 6 12 during adenosine, p 5 0.025; controls:
92 6 10 vs. 89 6 9 at rest, p 5 0.49; 78 6 11 vs. 77 6 5 during adenosine, p 5 0.75).
Similarly, contractility increased in ABM-treated pigs (ABM: 83 6 21 vs. 60 6 32 at rest,
p 5 0.04; 91 6 44 vs. 36 6 43 during pacing, p 5 0.056; controls: 69 6 48 vs. 64 6 46 at
rest, p 5 0.74; 65 6 56 vs. 37 6 56 during pacing, p 5 0.23).
CONCLUSIONS Bone marrow cells secrete angiogenic factors that induce endothelial cell proliferation and,
when injected transendocardially, augment collateral perfusion and myocardial function in
ischemic myocardium. (J Am Coll Cardiol 2001;37:1726–32) © 2001 by the American
College of Cardiology
The use of recombinant genes or growth-factors to enhance
myocardial collateral blood vessel function represents a new
strategy for the treatment of ischemic heart disease (1–9).
However, the natural processes leading to collateral devel-
opment are extremely complex, requiring multiple growth
factors interacting in concert and in sequence (10).
We have attempted to develop an approach utilizing natural
processes involved in collateral development, even though
these are largely unknown. Thus, bone marrow (BM) is a
natural source of multiple factors involved in angiogenesis,
including fibroblast growth factors 1 and 2 and vascular
endothelial growth factor (VEGF) (11,12). In addition, several
mediators known to be involved in hematopoiesis may also
regulate angiogenesis (13). These multiple cytokines are se-
creted by several cellular BM components, including stromal
cells and various hematopoietic cells (11,13–15). Finally, BM-
derived endothelial progenitor cells may be involved in post-
natal extramedullary angiogenesis (16,17).
Therefore, in the current investigation we tested the validity
of the following hypothesis: “In a porcine coronary occlusion
model, direct delivery of freshly aspirated autologous BM
(ABM) cells into ischemic myocardium enhances collateral
flow delivery and improves myocardial function.” We also
sought to define whether the BM cells obtained under the
specific conditions employed in this investigation secreted
potent angiogenic cytokines that may be important cofactors
involved in collateral function in ischemic myocardium.
METHODS
In Vitro Studies
Pig BM culture. Bone marrow cells were harvested from
pigs with chronic myocardial ischemia and filtered sequen-
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tially using 300m and 200m stainless steel mesh filters. Bone
marrow cells were then isolated by Ficoll-Hypaque gradient
centrifugation and cultured in long-term culture medium
([LTCM] Stem Cell Tech, Vancouver, British Columbia,
Canada) at 33°C with 5% CO2. Weekly, half of the medium
was removed and replaced with fresh LTCM. The removed
medium was filtered (0.2m filter) and stored at 220°C for
subsequent enzyme-linked immunosorbent assay (ELISA)
and cell proliferation assays.
Isolation and culture of pig aortic endothelial cells
(PAEC). Fresh PAEC were isolated as previously de-
scribed (18) and cultured using standard techniques. Their
identity was confirmed by typical endothelial cell morphol-
ogy and by positive antifactor VIII staining.
Effects of conditioned medium on PAEC proliferation
and DNA synthesis. Pig aortic endothelial cells (passages
3 to 10) were transferred to 96-well culture plates at a
density of 5,000 cells/well. Cells were cultured for two to
three days before being used in proliferation and DNA
synthesis experiments. The conditioned medium of BM
cells cultures, collected at four weeks, were pooled from
seven culture flasks and used in the assay. Aliquotes (10 mL,
30 mL, 100 mL or 200 mL) of pooled conditioned medium
or LTCM (200 mL, as control) were added to confluent
PAEC in 96 well plates in triplicate. Four days after culture
with conditioned medium or control medium, the PAEC
were trypsinized and counted (Coulter Counter Beckman
Corporation, Miami, Florida). DNA synthesis was assayed
at two days after the same culture conditions. One mCi
tritiated thymidine was added to each well. Forty-eight
hours later, DNA in PAEC was harvested (Mach III M
Tomtec, Hamden, Connecticut); radioactivity was counted
by liquid scintillation counter (Multidetector Liquid Scin-
tillation Luminescence Counter EG&G Wallac, Turku,
Finland).
Determination of VEGF and macrophage chemoattrac-
tant protein-1 (MCP-1) in conditioned medium. The
concentration of VEGF in conditioned medium was mea-
sured using sandwich ELISA kit (Chemicon International
Inc., Temecula, California), and MCP-1 was assayed by
sandwich enzyme immunoassay kit (R & D Systems,
Minneapolis, Minnesota) according to the manufacturer’s
directions.
In vivo study. The animal study was approved by the
Animal Care and Use Committee of the MedStar Research
Institute. The protocol conformed to the tenets of the
American Heart Association on research animal use. Four-
teen specific-pathogen-free domestic pigs weighing approx-
imately 35 to 40 kg underwent ameroid constrictor implan-
tation around the proximal left circumflex artery. Four
weeks later, all pigs underwent: 1) selective left and right
coronary angiography, 2) transthoracic echocardiography, 3)
regional myocardial blood flow assessment, and 4) electro-
mechanical left ventricular mapping. Following these pro-
cedures, all animals received morphine sulfate 3 mg intra-
muscularly every 8 h to alleviate postprocedural related
discomfort.
Treatment groups. In a pilot study, we evaluated the
feasibility and safety of transendocardial injection of ABM
using a tip-deflecting injection catheter (Biosense-Webster,
Diamond Bar, California) in 10 ischemic pigs. Each injec-
tion site was marked by adding Fluoresbrite YG 2.0 mm
microspheres (Polysciences, Inc. Warrington, Pennsylvania)
to ABM in a 1 to 9 ratio. Ten injections of 0.2 ml were
evenly distributed approximately 1 cm apart, within the
ischemic region and its boundaries (lateral wall, n 5 5) and
within the nonischemic territory (anterior-septal wall, n 5
5). Animals were sacrificed at 1, 3, 7 and 21 days (n 5 2 in
each time point). Two additional animals were also sacri-
ficed at three weeks after 0.5 ml of ABM injections.
In the second phase, animals were randomized to receive
12 injections of 0.2 ml each of freshly harvested ABM
aspirate (n 5 7) or a similar volume of heparinized saline
(n 5 7) directed to the ischemic area and its boundaries in
a similar fashion to the pilot study. Heart rate and systemic
blood pressure were measured continuously, and left atrial
pressure was recorded during the myocardial blood flow
studies.
An additional seven animals without myocardial ischemia
were studied to determine whether transendocardial injec-
tion of ABM into normal myocardium increases regional
blood flow. Animals were randomized to injections of ABM
(n 5 4) or heparinized saline (n 5 3) into the lateral wall as
described above.
BM aspiration and preparation. Immediately after com-
pletion of the baseline assessment, animals underwent BM
aspiration from the left femoral shaft using standard tech-
niques. Bone marrow was aspirated from two sites (3 ml per
site) using preservative-free heparinized glass syringes (20 U
heparin/1 ml fresh BM). The bone marrow was immedi-
ately macrofiltered using 300m and 200m stainless steel
filters, sequentially.
Left ventricular mapping procedure. The procedure has
been described in detail (19,20). The reconstructed left
ventricular electromechanical maps guided direct transmyo-
cardial injections using previously described electromechan-
ical coupling parameters (21).
Echocardiography study. Transthoracic echocardiography
(Hewlett-Packard Sonos 1000) image views at the midpap-
illary muscle level were recorded at rest and during 2 min of
right atrial pacing (temporary electrode, 180/min); frac-
tional shortening measurements were obtained as described
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(21). After being digitized and stored in a frame-grabber
board (Kodak ImageVue Compact Version 3.02, Eastman
Kodak Company, Pennsylvania), the average of three mea-
surements (taken from three different late-recorded frames)
in each examined region was used for analysis.
Angiographic collateral flow assessment. Each coronary
angiography study included dedicated injections to detect
late collateral dependent filling of the occluded left circum-
flex artery or its major branches. Angiographic collateral
flow was assessed using the Rentrop semiquantitative (0 to
3) score system for both left to left and right to left selective
coronary injection (22).
Regional myocardial blood flow. Fluorescent colored mi-
crospheres (23) (Interactive Medical Technologies, West
Los Angeles, California) were used to assess regional
myocardial blood flow at rest and during maximal coronary
vasodilation induced by infusing adenosine at a constant rate
of 140 mg/kg/min (Fujisawa USA, Deerfield, Illinois).
Measurements were quantified by the reference sample
technique (24). Two central 7-mm thick slices were each
divided into 16 endocardial (n 5 8) and epicardial (n 5 8)
subsegments, as previously described (3,4). The average of
eight lateral ischemic zone and eight septal normal zone
subsegments measurements was used to assess endocardial
and epicardial regional myocardial blood flow. Relative
collateral flow was also computed as described (3).
Histopathology. Standard BM smears were prepared be-
fore and after propelling freshly filtered ABM aspirate
Figure 1. (A) Effects of conditioned medium on PAEC proliferation. Pig aortic endothelial cells were seeded, in triplicate, in 96 well plates for one day;
subsequently, the indicated volumes of conditioned medium from pooled samples or control medium were added (with comparable volume of PAEC
medium removed). After four days, PAEC, cultured with conditioned medium or control medium, were harvested and counted. (B) Effects of conditioned
medium on tritiated thymidine uptake by PAEC. After two days, 1 mCi tritiated thymidine was added to each well, and 48 h later, DNA in PAEC was
harvested, and radioactivity was counted. (C and D) Changes in bone marrow cell conditioned medium of VEGF (C) and MCP-1 (D) concentrations at
one to four weeks, assayed by ELISA. MCP-1 5 macrophage chemoattractant protein-1; PAEC 5 pig aortic endothelial cells; VEGF 5 vascular
endothelial growth factor.
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through the needle using similar injecting pressure as in the
in vivo study.
In the pilot study, identified fluorescent-labeled areas
were cut into three full thickness adjacent blocks,
immersion-fixed and stained with hematoxylin and eosin
(H&E) and periodic acid-Schiff. Fluorescent-labeled tissues
obtained from the ischemic region were snap-frozen and
stained for CD-34, a marker of BM-derived progenitor
cells, using monoclonal mouse antibody as primary antibody
(Becton Dickinson, San Jose, California).
In the efficacy study phase, full-thickness, 1.5 cm3 sec-
tions from ischemic and nonischemic regions were pro-
cessed for paraffin sections. Each sample was stained with
H&E, Masson’s trichrome and factor VIII related antigen.
Vascularity, including total area occupied by any blood
vessel, the number of these vessels and those with a diameter
larger than 50 mm, was assessed, as previously described
(25).
Density of endothelial cells was assessed using Sigma-
Scan Pro morphometry software (SPSS Science, Chicago,
Illinois) and the intensity threshold method. Total endo-
thelial area for each sample and for each specimen was
obtained along with relative percent endothelial area (endo-
thelial area/area of myocardium studied). Similar analysis
was performed for noninfarcted (viable) myocardium after
excluding trichrom-positive stained areas.
Statistics. Unpaired and paired Student t tests were used
for comparison of nominal and normalized values between
and within groups, respectively. Wilcoxon rank-sum test
was used when test for normal distribution failed. Repeated
measure of variance was used to compare the concentration
of VEGF and MCP-1 in the control medium or BM-
conditioned medium collected at weeks 1, 2, 3 and 4.
One-way analysis of variance (ANOVA) was used to
compare the effects of conditioned medium on PAEC
proliferation and tritiated thymidine uptake by PAEC. All
results are presented as mean 6 SD. A p value ,0.05 was
considered as statistically significant.
RESULTS
In Vitro Study
Conditioned medium-induced proliferation of porcine
aortic endothelial cells. The BM-conditioned medium
collected at four weeks increased proliferation of PAEC as
determined by both direct counting and measuring tritiated
thymidine uptake (p , 0.001 for both; Fig. 1, A and B) in
a dose-related manner. When LTCM was completely
replaced by BM-conditioned medium (200 mL), the ob-
served stimulatory effect diminished. Similar dose-related
results were observed in the tritiated thymidine uptake
studies.
BM cells staining for factor VIII. Limited number (5% 6
4%) of freshly aspirated BM cells stained positive for factor
VIII. This contrasted with 57% 6 14% of the adherent layer
of BM cells cultured for four weeks, of which 60% 6 23%
were endothelial-like cells and 40% 6 28% appeared to be
megakaryocytes.
VEGF and MCP-1 in BM-conditioned medium and in
control medium. Over four weeks, concentrations of
VEGF and MCP-1 in BM-conditioned medium increased
gradually to seven and three times the first week level,
respectively (Fig. 1, C and D). Vascular endothelial growth
factor and MCP-1 levels in a control culture medium, not
exposed to BM, were 0 and 11 6 2 pg/ml, respectively.
In vivo study. Fourteen of 20 pigs completed the study. At
intervention, weight was similar between groups (ABM vs.
controls 5 68 6 4 vs. 69 6 4 kg). Five died suddenly within
three weeks of ameroid implantation (before ABM injec-
tion), presumably from ameroid-induced abrupt coronary
occlusion. All animals survived the BM aspiration and
catheter-based intramyocardial injections. One animal, ran-
domized to the ABM-treated group, experienced acute
myocardial ischemia during ameroid implantation and died
seven days before study termination. All animals were
hemodynamically stable, and no differences were noted
between groups in heart rate, mean blood pressure or mean
left atrial pressures at baseline and at four-week follow-up
(data not shown).
Myocardial function. Preintervention relative fractional
wall thickening, at rest and during pacing, was similar
between groups (p 5 0.86 and 0.96, respectively; Table 1).
At four weeks, regional wall thickening improved at rest and
during pacing, due to an approximately 50% increase in wall
thickening of the ischemic lateral wall. No significant
changes were observed in the control animals.
Myocardial perfusion. Preintervention measurements
were similar between treated and control groups at rest and
during adenosine infusion (Table 2). At four weeks, relative
regional transmural myocardial perfusion at rest and during
Table 1. Regional Contractility of the Ischemic Wall*
Baseline Follow-Up p Value
Rest
ABM (%) 60 6 32 83 6 21 0.04
Control (%) 64 6 46 69 6 48 0.74
Pacing
ABM (%) 36 6 43 91 6 44 0.056
Control (%) 37 6 56 65 6 56 0.23
*Fractional shortening measurements were obtained by measuring % wall thickening
(end-systolic thickness minus end-diastolic thickness/end-diastolic thickness) 3 100,
and then the ischemic territory value (lateral area) was divided by the nonischemic
value (anterior-septal area).
ABM 5 autologous bone marrow.
Table 2. Regional Myocardial Perfusion in Ischemic Animals
Baseline Follow-Up p Value
Rest
ABM (%) 83 6 12 98 6 14 0.001
Control (%) 89 6 9 92 6 10 0.49
Adenosine
ABM (%) 78 6 12 89 6 18 0.025
Control (%) 77 6 5 78 6 11 0.75
ABM 5 autologous bone marrow.
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pacing improved significantly in the ABM-treated group.
This was due to an absolute improvement in myocardial
perfusion in the ischemic zone both at rest (increase of 57%,
p 5 0.08) and during adenosine infusion (increase of 37%,
p 5 0.09), while no significant changes were noted in
absolute flow to the nonischemic zone either at rest (in-
crease of 35%, p 5 0.18) or during adenosine infusion
(increase of 25%, p 5 0.26). Regional rest myocardial blood
flow to the ischemic zone increased both in the endocardial
(73%) and epicardial (62%) segments, with somewhat lesser
improvement during adenosine infusion (40% in both
zones). There were no pre- versus postintervention differ-
ences in regional myocardial perfusion in the ischemic and
nonischemic zones in the control group.
Injection of ABM into nonischemic myocardium did not
improve relative regional myocardial blood flow either under
baseline conditions (ABM: 0.92 6 0.04 vs. 0.95 6 0.02 at
four weeks, p 5 0.27; control: 0.97 6 0.04 vs. 0.98 6 0.04,
p 5 0.63) or during the infusion of adenosine (ABM:
0.93 6 0.07 vs. 0.95 6 0.07, p 5 0.54; control: 1.01 6 0.09
vs. 1.02 6 0.16, p 5 0.93).
Angiographic assessment of collateral flow. Baseline left
to left and right to left collateral scoring was similar between
groups. At four weeks, no significant improvement was
noted in either of the two groups (ABM left to left
collaterals: 1.3 6 1.2 vs. 1.4 6 1.0 at four weeks, p 5 1.0
and right to left collaterals 0.7 6 0.5 vs. 1.0 6 1.2, p 5 0.46;
control: 2.0 6 1.2 vs. 2.4 6 0.8, p 5 0.25 and right to left
collaterals 0.9 6 1.1 vs. 0.6 6 0.8, p 5 0.46).
Histopathology and vascularity assessment. Bone mar-
row smears before and after passing the filtrated aspirate
through the injection catheter revealed normal morphology,
absence of macroaggregates and no evidence of cell frag-
ments or distorted cell shapes. Histopathology at day 1 after
injections revealed acute lesions characterized by a needle
tract containing fibrin and mononuclear cells that morpho-
logically could not be differentiated from BM cells. Cellu-
larity was maximal at three and seven days and declined
subsequently over time. At three weeks, more fibrosis was
seen in the 0.5-ml injection sites compared with the 0.2-ml
sites. Overall, approximately 4% to 6% of the cellular
infiltrate showed positive immunoreactivity to CD-34 (Fig. 2).
The ischemic territory in both groups was characterized
by small areas of patchy necrosis occupying overall ,10% of
the ischemic myocardium without evidence for inflamma-
tion (Table 3). The nonischemic area revealed normal
myocardial structure. There were no differences in total area
occupied by any blood vessel or in the number of blood
vessels .50 mm in diameter. However, comparison of the
total areas staining positive for factor VIII (endothelial cells
with or without lumen) revealed a 100% increase in total
endothelial cell area in the ischemic collateral-dependent
Figure 2. Myocardial injection site stained for CD-34 (left) and hematoxylin and eosin (right) at three days after transendocardial injection of ABM. Note
strong staining for CD-34 in 4% to 6% of the cells.
Table 3. Histopathologic Quantification of Vascularity
ABM Control p Value
Ischemic zone
No. of blood vessels .50 mm/4 mm2 22.9 6 15.5 20.1 6 17.3 0.76
All blood vessels (% area) 4.0 6 2.5 3.4 6 2.9 0.69
Endothelial cells (% area) 11.6 6 5.0 12.3 6 5.5 0.81
Infarcted tissue (% area) 5.9 6 7.4 9.1 6 7.1 0.43
Endothelial cells in noninfarcted
tissue (% area)
12.5 6 5.9 13.7 6 6.3 0.72
Nonischemic zone
No. of blood vessels .50 mm/4 mm2 28.2 6 17.7 16.2 6 9.2 0.14
All blood vessels (% area) 4.2 6 3.1 2.8 6 1.5 0.32
Endothelial cells (% area) 5.7 6 2.3 8.2 6 3.1 0.12
ABM 5 autologous bone marrow.
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zone compared with the nonischemic territory (11.6% 6
5.0% vs. 5.7% 6 2.3% area, p 5 0.016) of the ABM-treated
group, whereas there was no significant difference in the
control group (12.3% 6 5.5% vs. 8.2% 6 3.1% area, p 5
0.11). Other parameters of vascularity, including percentage
of the area occupied by any blood vessel and number of
blood vessels .50 mm were similar in the ischemic and
nonischemic territories in both groups.
DISCUSSION
In this investigation, we tested the concept that collateral
flow may be enhanced by using the natural ability certain
cells and tissues have to secrete angiogenic factors in a
time-appropriate manner, even though such processes are
largely unknown. The results indicate such a strategy is
valid.
We found that direct delivery of freshly aspirated ABM
into ischemic porcine myocardium enhances collateral flow
and improves myocardial function. The concordant changes
in these two separately measured, but functionally depen-
dent, parameters of collateral flow adds further support to
the conclusion that injection of ABM into ischemic tissue
initiates and sustains biologically relevant angiogenic re-
sponses. No change in collateral flow was observed when
ABM was injected into normal nonischemic myocardium.
In vitro study. In these experiments, we found several
possible contributing factors that may mediate BM cell-
induced increase in collateral flow. First, BM cells in culture
produced large amounts of VEGF, a potent angiogenic
growth factor (3,7,10), and MCP-1, which has been iden-
tified as a mediator of arteriogenesis, a process whereby
remodeling of preexisting larger-sized blood vessels occurs,
increasing their capacity to deliver blood (26). In addition,
the conditioned medium of BM cells (containing secreted
products of the cells) induced proliferation of vascular
endothelial cells in a dose-related manner. Whether this
effect was caused solely by the increased amounts of VEGF
and MCP-1 measured or was also contributed to by other,
as yet unknown, molecules is uncertain. In addition, we
found in vitro a substantial time-related increase in the
number and proportion of BM-derived endothelial cells. It
is possible that proliferating endothelial cells derived from
the injected ABM contributed to collateral development via
incorporation into expanding collateral vessels (16); this
concept, however, is still controversial (27). Finally, it is
possible that the mild transient inflammatory effect we
observed to occur the first few days after the injection of the
BM cells may have contributed to the initiation of the
angiogenic process.
In vivo studies. The substantial increase in myocardial
perfusion we observed was not accompanied by histological
evidence of an increased number of capillaries or large blood
vessels. Such a discrepancy, also encountered in previous
studies (28,29), undoubtedly reflects the very small increases
in diameter necessary to effect biologically significant de-
creases in resistance to collateral flow and the sensitivity of
the histologic and angiographic measures we employ to
detect such changes, even with detailed methods of angio-
graphic analysis (30). In addition, in the ameroid pig model,
standard angiographic assessment may be suboptimal, as
extracardiac collaterals, which are not assessed by conven-
tional angiography, account for up to 30% of collateral flow
at rest (31).
Catheter-based transendocardial injection had previously
been used successfully to deliver solutions such as methylene
blue (32) or reporter genes (33), but not cells. The normal
BM smears, the positive intramyocardial CD-34 staining at
three days after ABM injection and the effects on collateral
flow indicate that such an approach does not compromise
the function of injected cells. Our study, therefore, estab-
lishes, for the first time, the feasibility of a catheter-based
transendocardial approach for direct myocardial cell trans-
plantation, a far less invasive procedure than currently
available surgical techniques (27).
The evidence that freshly aspirated ABM transplantation
into ischemic myocardium is associated with improved
collateral flow without adverse effects in the pig model of
myocardial ischemia suggests that this strategy may be of
clinical importance. Such a strategy would also probably be
less costly than many other currently tested angiogenic
strategies and would avoid potential toxicity-related issues
that, although remote, are definite possibilities with various
gene-based approaches using viral vectors.
In summary, the results of this investigation indicate that
BM cells secrete potent angiogenic cytokines such as VEGF
and MCP-1 and induce proliferation of BM-derived, as
well as vascular, endothelial cells. They also show that
catheter-based transendocardial injection of ABM is feasi-
ble, a strategy resulting in enhanced collateral perfusion and
improved mechanical function of ischemic myocardium.
These results suggest that clinical studies may now be
appropriate to determine whether this novel therapeutic
strategy may be an effective way to achieve therapeutic
enhancement of collateral development.
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